中国青年报客户端讯（中青报·中青网记者刘言）第十届北京国际医药健康交流会暨京津冀医药产业协 同展示活动12月19日在北京市大兴区营商服务中心举行，来自京津冀三地的政府部门、科研机构、高等 院校、医疗机构、领军企业及行业组织的代表200余人，共同回顾发展成就、剖析时代挑战、擘画未来 蓝图，为推动医药健康产业创新协同与高质量发展凝聚广泛共识。 据介绍，本届大会以"擘画笃行，医药产业高质量发展新航程"为主题，旨在深入贯彻国家推动医药产业 高质量发展的战略部署，全面落实创新驱动发展要求，积极构建医药健康产业新生态，持续推动京津冀 协同发展迈向更高阶段。 河北省工业和信息化厅总工程师毛红领通过视频连线介绍了河北生物医药产业的发展成果。他表示，河 北省正以更大力度深化与京津合作，围绕生物医药产业发展需求，以企业为主体，联合高校、科研院所 组建创新联合体，整合各方资源，构建协同创新机制。 交流活动设置了"医药产业高质量发展"主场交流、"生物医药协同发展新征程"京津冀活动专场以及"多 元化发展的北京中药"中医药专场活动三个平行分论坛，与会专家、企业代表聚焦医疗器械创新监管、 京津冀生物医药协同发展以及推动中医药产业高质量发展 ...

Core Viewpoint - The article emphasizes the importance of establishing a robust standard system in the Guangdong-Hong Kong-Macao Greater Bay Area to support high-quality development and enhance global competitiveness through regional collaboration and international standardization efforts [1][4]. Group 1: Standard System Development - The Greater Bay Area has jointly announced 262 "Bay Area Standards" covering 36 fields, including transportation, water conservancy, traditional Chinese medicine, green ecology, and elderly care, creating a positive ecosystem driven by government guidance, market leadership, and collaboration among the three regions [1]. - A focus on emerging industries and future sectors is essential to build a forward-looking standard system that guides industrial upgrades and provides regulatory support, particularly in artificial intelligence and digital economy sectors [2][3]. Group 2: Internationalization and Regional Collaboration - The article discusses the need for a dual empowerment mechanism of "standard internationalization + regional collaboration" to enhance global rule-making power, advocating for the integration of Bay Area standards with international standards [4][5]. - Strengthening regional collaboration and establishing a multi-level international cooperation network is crucial, including standard mutual recognition mechanisms with countries along the Belt and Road Initiative [5]. Group 3: Implementation and Governance - A "technology empowerment + governance innovation" framework is proposed to ensure effective implementation of standards, utilizing advanced technologies like big data and artificial intelligence for real-time monitoring and evaluation [6][7]. - The establishment of incentive mechanisms for enterprises adopting Bay Area standards is recommended, including tax benefits and funding support, to encourage compliance and participation in standard formulation [7].

Core Insights - The "Zhongxing·Changbai Qihuang" Traditional Chinese Medicine (TCM) AI model 1.0 has been officially launched, marking a significant breakthrough in the integration of TCM and artificial intelligence in Jilin Province [1][2] - The project is led by Professor Leng Xiangyang from Changchun University of Chinese Medicine and aims to develop an AI-native multimodal reasoning model tailored for TCM scenarios [1] - The model focuses on real diagnostic and health management needs, incorporating multimodal information such as images, voice, and video to enhance long-term understanding and reasoning capabilities [1] Application and Features - The 1.0 version includes two main applications: "Family Health Assistant" for the general public, providing practical health guidance, and "Jipai TCM Doctor Assistant" aimed at young TCM practitioners and medical students, offering digitalized insights into diagnostic thinking and medication logic [1] - The project also aims to convert the implicit experiences of renowned TCM masters into traceable and shareable digital knowledge, enhancing the accessibility of quality TCM resources in remote and aging areas [2] - Future iterations of the model (versions 2.0 and 3.0) are planned to achieve verifiable and deep integration of the four diagnostic methods, providing sustainable technical support for the innovative development of "AI+TCM" in Jilin [2]

列珍贵实物展品，吸引各界嘉宾驻足观看。 记者 陈悦 摄 马来西亚国会议员陈国伟、中国驻马来西亚大使馆公使郑学方、中国文物保护基金会秘书长陶诚、中国 华侨历史博物馆副馆长(主持工作)宁一、马来西亚中华大会堂总会总会长林家全、马来西亚中华总商会 总会长吴逸平、马来西亚华人医药总会总会长何德君等各界嘉宾百余人出席开幕式。开幕式上，广州白 云山医药集团和岭南中医药博物馆的代表向中国华侨历史博物馆、马来西亚华人博物馆捐赠了中医药历 史文化展品；中马两国中医药从业者分享了中医药文化故事。 展览中陈 据介绍，本次展览是中国侨联践行"弘扬中华文化、促进中外交流"使命的具体举措、国家文物局"文明 桥梁计划"首批精品项目。展览由中国侨联、中国国家文物局指导，中国华侨历史博物馆、马来西亚华 人博物馆、宁波博物院、广州华侨博物馆联合主办，多家中马机构协办。(完) 中新网吉隆坡12月20日电 (记者 陈悦)"一脉岐黄——华侨华人与中医药文化展"20日在马来西亚吉隆坡 开幕。 此次展览以"文明互鉴、药香传情"为核心脉络，精选200余件珍贵实物、图片及丰富影像资料，设置"厚 朴贯众：中华文明的瑰宝中医药""海月南星：早期中医药文化的传播" ...

Group 1 - The article highlights the establishment of a "preventive treatment" service system in Mingguang City, Anhui Province, focusing on traditional Chinese medicine (TCM) to address health concerns of the local population [3] - The initiative includes practical activities such as practicing health exercises and learning TCM health knowledge at the Mingguang City Traditional Chinese Medicine Hospital [1] - The local government aims to shift the focus of TCM services closer to the community, enhancing accessibility and promoting preventive healthcare measures [3]

前言 投资信息如迷雾？市场节奏总踏空？那是你缺少利器！想精准捕捉研报价值？想抢占投资先机？《行研 精选》为你破局！覆盖每个交易日，从事件中发现机会，提炼研报精华，助力捕捉行业风口。 12月18日，香港特区政府发布首份《中医药发展蓝图》。《蓝图》就各主要范畴制定短、中和长期 目标及行动计划，涵盖五大领域，并提出8个目标及20个行动。 二、特朗普60亿美元跨界核聚变，商业化进程按下加速键 当地时间12月18日，特朗普媒体科技集团（DJT）发布公告称与一家获得Alphabet支持的核聚变能 源公司TAE Technologies签署最终合并协议，双方将通过全部股票交易合并，交易价值超过60亿 美元。 点击付费阅读，挖掘行业机会，把握投资风口！ 【 精选快读 】 一、中医药赛道迎重磅利好，香港首份产业发展蓝图落地 ...

Core Viewpoint - The Hong Kong government has officially released the "Traditional Chinese Medicine Development Blueprint," which aims to promote comprehensive, high-quality, and high-level development of traditional Chinese medicine (TCM) in Hong Kong [1][2] Group 1: Development Goals - The blueprint includes eight goals, such as optimizing clinical services, establishing a cross-professional service system, and leading the development of TCM professionals [1][2] - Goals also focus on enhancing the quality of Chinese medicine, establishing international standards, driving research and innovation, promoting TCM culture, and facilitating the global outreach of TCM services [2] Group 2: Industry Outlook - CITIC Securities indicates that the short-term pressure on the Chinese medicine industry is expected to ease, with channel inventory clearing accelerating and demand expected to recover by year-end [1][3] - Huajin Securities emphasizes the importance of the "premium + innovation" strategy in the Chinese medicine sector, highlighting the strong brand effect and pricing power of premium Chinese medicine products [3] Group 3: Company Highlights - China Traditional Chinese Medicine (00570) reported a revenue of approximately 7.46 billion RMB for the first half of 2025, a year-on-year decrease of 11.0%, with a gross profit of about 3.63 billion RMB, down 10.5% [5] - Tong Ren Tang (03613) is a historic brand in the Chinese medicine industry, producing over 400 types of traditional Chinese medicine products [6] - Guo Sheng Tang (02273) is actively expanding its presence in Singapore through a strategy of mergers, partnerships, and self-built initiatives [6] - Baiyunshan (00874) reported a revenue of 61.606 billion RMB for the first three quarters of 2025, an increase of 4.31% year-on-year, with a net profit of 3.31 billion RMB, up 4.78% [6]

Core Viewpoint - The Hong Kong government has officially released the "Traditional Chinese Medicine Development Blueprint," aiming to promote comprehensive, high-quality, and high-level development of traditional Chinese medicine (TCM) in Hong Kong, encompassing five areas, eight goals, and twenty actions [1][2]. Group 1: Development Goals - The eight goals include optimizing clinical services, establishing a cross-professional service system, leading the development of TCM professions, enhancing the quality of TCM, building international standards for TCM, driving research and innovation in the industry, promoting TCM culture, and facilitating the global outreach of TCM [1][2]. - The government aims to enhance the quality of TCM services and integrate them into the healthcare system, thereby improving public health and establishing Hong Kong as a bridge for TCM to the world [2][3]. Group 2: Industry Outlook - CITIC Securities indicates that the short-term pressure on the TCM industry is expected to ease, with channel inventory clearing accelerating, and anticipates a demand rebound by year-end, along with opportunities for fundamental and valuation improvements [1][3]. - Huajin Securities emphasizes the importance of the "premium + innovation" strategy in the TCM sector, highlighting that premium TCM products possess significant medical value and consumer attributes, while innovative TCM is gradually entering a harvest period supported by favorable policies [3][4]. Group 3: Company Highlights - China Traditional Chinese Medicine (00570) reported a revenue of approximately 7.46 billion RMB for the first half of 2025, a year-on-year decrease of 11.0%, with a gross profit of about 3.63 billion RMB, down 10.5%, but with a gross margin of 48.7%, up 0.3 percentage points from the previous year [5]. - Tong Ren Tang (03613), a historic brand in the TCM industry, produces over 400 types of traditional Chinese medicine, covering various medical fields [5][6]. - Guo Sheng Tang (02273) is actively expanding its TCM services in Singapore through a strategy of mergers, partnerships, and self-built initiatives, including a recent joint venture with a digital healthcare platform [6]. - Baiyunshan (00874) reported a revenue of 61.606 billion RMB for the first three quarters of 2025, an increase of 4.31% year-on-year, with a net profit of 3.31 billion RMB, up 4.78% [6].

Core Viewpoint - The Hong Kong government has officially released its first "Traditional Chinese Medicine Development Blueprint," aiming to enhance the quality and level of the TCM industry and position Hong Kong as a global hub for TCM promotion and innovation [1][2] Group 1: Objectives and Actions - The blueprint outlines eight major goals and 20 specific actions across five key areas: TCM services, TCM professionals, TCM development, cultural heritage, and global outreach [1] - A primary goal is to optimize clinical services, establishing a clear role for TCM within the healthcare system, highlighting areas of strength, and planning service strategies [1] Group 2: Integration and Collaboration - The government plans to establish a cross-professional collaboration system for TCM services, creating clear clinical guidelines and referral processes to enhance cooperation between TCM and Western medicine, rehabilitation therapists, and other professionals [1] - This initiative aims to provide integrated and diverse medical services to patients through seamless resource sharing among different healthcare institutions [1] Group 3: Community and Professional Development - The blueprint emphasizes strengthening the core role of TCM in primary healthcare, with plans to enhance the TCM service network at the community level [2] - A comprehensive TCM service system will be developed, initially covering 23 TCM advantage disease categories, with plans to expand to 35, allowing residents to access targeted TCM services conveniently [2] - The blueprint also focuses on advancing TCM professional development, establishing a multi-tiered training system that includes education, post-graduate training, and continuing education to cultivate a high-quality TCM workforce [2]

Core Viewpoint - The Chinese medicine sector is expected to see a recovery in demand by the end of the year, with easing short-term base pressure and accelerated channel inventory clearance, presenting opportunities for fundamental and valuation improvements [1] Group 1: Short-term Outlook - CITIC Securities indicates that the short-term base pressure in the traditional Chinese medicine industry is likely to ease, leading to a recovery in demand by year-end [1] - The acceleration of channel inventory clearance is expected to support this recovery [1] Group 2: Growth Drivers - Innovation in the sector is seen as a key driver for constructing a second growth curve, with significant brand extension opportunities for traditional Chinese medicine consumer goods companies [1] - The adjustment of the basic medicine catalog is anticipated to catalyze a new round of market activity in traditional Chinese medicine [1] Group 3: Performance Trends - According to Cinda Securities, some traditional Chinese medicine stocks are showing trends of revenue and profit improvement by the third quarter of 2025, with seasonal flu in autumn and winter potentially boosting performance [1] - Huajin Securities emphasizes the importance of focusing on two main lines in the traditional Chinese medicine sector: "premium + innovation" [1] Group 4: Premium and Innovation Focus - Premium traditional Chinese medicine products combine medical value with consumer attributes, demonstrating significant brand effects and strong pricing power among high-net-worth clients [1] - Innovative traditional Chinese medicine, supported by favorable policies and positive external stimuli, is gradually entering a harvest period, with modified new drugs and classic ancient formulas expected to accelerate clinical development and commercialization [1]